


1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

708 Supplementary Figure 1. Nebulizers used in the studies. (A) The AeroLife™ device is an aerosol
709 delivery device which has FDA 510K approval for delivery of asthma medications. The device
710 (right) is attached to an external battery pack (left). The device was modified to include a
711 capillary pump (center) to provide a constant supply of the large volume of vaccine needed for
712 the animal studies. In one of the DDCs is connected to the pump. (B) The AeroVax™ is a newer,
713 smaller, prototype device with an internal battery pack, no added airflow and breath actuation of
714 aerosolization, which was not used in this study. A capillary pump (not shown) was also used
715 with the AeroVax™ device in this study.



722 Supplementary Figure 2. Particle Size Distribution (PSD) Data for AeroVax™ and AeroLife™
723 Nebulizers and the Accuspray™ Spray Device.

